We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Medgenics(Regs) | LSE:MEDG | London | Ordinary Share | COM SHS USD0.0001 (REGS) |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 302.50 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Jul 2019 to Jul 2024
TIDMMEDG TIDMMEDU
RNS Number : 7033U
Medgenics Inc
04 December 2013
Press Release 04 December 2013
Directors Dealings
Medgenics, Inc. (AIM: MEDU, MEDG and NYSE MKT: MDGN), the developer of Biopump(TM) , a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces that on 2 December 2013 and 3 December 2013, the Company was informed by Dr. Eugene Bauer, a Director of the Company, that he sold a total of 20,000 shares of common stock on the open market on those days at an average price of $6.30 per share.
Following this sale Dr. Bauer owns 195,874 shares of common stock representing approximately 1.1 per cent of the issued share capital. Dr. Bauer also has the right to purchase up to 78,571 shares of common stock pursuant to warrants and options previously granted (in aggregate Dr. Bauer's shares of common stock, warrants, and options represent 274,445 shares of common stock which represent approximately 1.5 per cent of the issued share capital).
This announcement is being made pursuant to the London Stock Exchange's AIM Rules for Companies admitted to trading on the AIM market.
About Medgenics
Medgenics is developing and commercializing Biopump(TM), a proprietary tissue-based platform technology for the sustained production and delivery of therapeutic proteins using the patient's own tissue for the treatment of a range of chronic diseases including anemia, hepatitis, among others. For more information, please visit www.medgenics.com.
Contacts:
Medgenics, Inc. John Leaman, CFO john.leaman@medgenics.com LHA Anne Marie Fields 212-838-3777 afields@lhai.com @LHA_IR_PR Abchurch Communications Joanne Shears / Jamie Hooper / Harriet Rae harriet.rae@abchurch-group.com +44 207 398 7718 Oriel Securities (NOMAD & Broker) Jonathan Senior / Giles Balleny +44 207 710 7617
-Ends-
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSUSAOROVAURAA
1 Year Medgenics(Regs) Chart |
1 Month Medgenics(Regs) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
